{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Comparator&page=31",
    "query": {
      "intervention": "Control Comparator",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 1670,
    "total_pages": 167,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Comparator&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Comparator&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T18:18:51.753Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01086748",
      "title": "A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LY2140023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denovo Biopharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1134,
      "start_date": "2010-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 19,
      "location_summary": "Escondido, California • Garden Grove, California • Paramount, California + 16 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01086748"
    },
    {
      "nct_id": "NCT00734591",
      "title": "Follow-Up Study for Exubera",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exubera",
          "type": "DRUG"
        },
        {
          "name": "Randomized diabetes therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7439,
      "start_date": "2008-08",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2012-10-23",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 131,
      "location_summary": "Bay Minette, Alabama • Graysville, Alabama • Pell City, Alabama + 111 more",
      "locations": [
        {
          "city": "Bay Minette",
          "state": "Alabama"
        },
        {
          "city": "Graysville",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00734591"
    },
    {
      "nct_id": "NCT02275936",
      "title": "Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "N91115",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nivalis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2015-02",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275936"
    },
    {
      "nct_id": "NCT07167966",
      "title": "Alzheimer's Tau Platform: Regimen A - AADvac1",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Preclinical Alzheimer's Disease",
        "Prodromal Alzheimer's Disease",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "AADvac1",
          "type": "DRUG"
        },
        {
          "name": "Donanemab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul S. Aisen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 450,
      "start_date": "2026-11-03",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Providence, Rhode Island • Nashville, Tennessee",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07167966"
    },
    {
      "nct_id": "NCT02134353",
      "title": "A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Inhaled mannitol",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: Arm B - Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syntara",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 423,
      "start_date": "2014-09",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 36,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02134353"
    },
    {
      "nct_id": "NCT05665595",
      "title": "A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab/Vibostolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1594,
      "start_date": "2023-01-19",
      "completion_date": "2025-09-24",
      "has_results": true,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 30,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05665595"
    },
    {
      "nct_id": "NCT06887829",
      "title": "Radio- KO Radiotherapy for Knee Osteoarthritis Clinical Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Low dose radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Sham comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "50 Years to 100 Years"
      },
      "enrollment_count": 128,
      "start_date": "2025-06-04",
      "completion_date": "2027-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06887829"
    },
    {
      "nct_id": "NCT06580145",
      "title": "Leucine in Midlife Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depression"
      ],
      "interventions": [
        {
          "name": "L-leucine",
          "type": "DRUG"
        },
        {
          "name": "L-lysine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 75,
      "start_date": "2025-02-01",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06580145"
    },
    {
      "nct_id": "NCT01578239",
      "title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoid Tumor of the Small Bowel",
        "Neuroendocrine Tumour"
      ],
      "interventions": [
        {
          "name": "Octreotide LAR",
          "type": "DRUG"
        },
        {
          "name": "177Lu-DOTA0-Tyr3-Octreotate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Accelerator Applications",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 231,
      "start_date": "2012-09-06",
      "completion_date": "2021-01-18",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01578239"
    },
    {
      "nct_id": "NCT03443869",
      "title": "Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "CMV Disease"
      ],
      "interventions": [
        {
          "name": "Letermovir",
          "type": "DRUG"
        },
        {
          "name": "Valganciclovir",
          "type": "DRUG"
        },
        {
          "name": "Acyclovir (ACV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ACV",
          "type": "DRUG"
        },
        {
          "name": "Placebo to LET",
          "type": "DRUG"
        },
        {
          "name": "Placebo to VGCV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 601,
      "start_date": "2018-05-03",
      "completion_date": "2022-04-05",
      "has_results": true,
      "last_update_posted_date": "2023-07-28",
      "last_synced_at": "2026-10-21T18:18:51.753Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03443869"
    }
  ]
}